The kidney is a major site of interferon catabolism, with filtration, reabsorption, and degradation occurring in tubular cells, which has implications for devising improved dosage schedules in clinical trials.
No takes yet. Share an insight, caveat, or question.
Renal IFN catabolism may inform dosing; animal data leaves open human translation.
Bocci et al. (1982) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: